Anal margin squamous cell carcinoma
diseaseOn this page
Also known as perianal skin squamous cell carcinomasquamous cell carcinoma of anal marginsquamous cell carcinoma of the anal margin
Summary
Anal margin squamous cell carcinoma (MONDO:0001470) is a cancer and 3 clinical trials. Top therapeutic interventions include fludeoxyglucose f 18 and nivolumab. A subtype of skin squamous cell carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 3
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | anal margin squamous cell carcinoma |
| Mondo ID | MONDO:0001470 |
| DOID | DOID:12239 |
| ICD-10-CM | C44.520 |
| NCIT | C6925 |
| SNOMED CT | 255084004 |
| UMLS | C1412037 |
| MedGen | 278071 |
| GARD | 0022948 |
| Anatomy (UBERON) | UBERON:0012336 |
| Is cancer (heuristic) | yes |
Also known as: anal margin squamous cell carcinoma · perianal skin squamous cell carcinoma · squamous cell carcinoma of anal margin · squamous cell carcinoma of the anal margin
Disease family
This is a subtype of skin squamous cell carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › integumentary system disorder › integumentary system cancer › skin cancer › skin carcinoma › skin squamous cell carcinoma › anal margin squamous cell carcinoma
Related subtypes (8): plantar verrucous skin carcinoma, sarcomatoid squamous cell skin carcinoma, skin basaloid carcinoma, acantholytic squamous cell skin carcinoma, pseudovascular skin squamous cell carcinoma, clear cell squamous cell skin carcinoma, skin squamous cell carcinoma in situ, skin adenosquamous carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 3.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 2 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03233711 | PHASE3 | ACTIVE_NOT_RECRUITING | Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer |
| NCT04166318 | PHASE2 | ACTIVE_NOT_RECRUITING | Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study |
| NCT04929028 | PHASE2 | ACTIVE_NOT_RECRUITING | Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FLUDEOXYGLUCOSE F 18 | 4 | 2 |
| NIVOLUMAB | 4 | 2 |
Related Atlas pages
- Drugs: FLUDEOXYGLUCOSE F 18, Nivolumab